Ulcerative colitis doesn’t have a single cause. It develops when several factors converge: genetic susceptibility, an immune system that turns against the colon’s own lining, shifts in gut bacteria, and environmental triggers that tip the balance. No one factor is enough on its own, which is why researchers describe it as a complex, multifactorial disease. Globally, about 120 people per 100,000 live with the condition, with the highest prevalence in Europe and the highest rate of new diagnoses in North America.
Genetics Set the Stage
Your genes don’t guarantee you’ll develop ulcerative colitis, but they heavily influence your risk. Genome-wide studies have identified more than 240 regions of DNA linked to inflammatory bowel disease, and roughly two-thirds of those overlap between ulcerative colitis and Crohn’s disease. The strongest genetic associations involve a set of immune-related genes called HLA class II, particularly a variant known as HLA-DRB1*0103, which is tied to more extensive inflammation across the colon.
Twin studies help put the genetic contribution in perspective. Among identical twins, if one has ulcerative colitis, the other develops it about 10 to 15% of the time. For fraternal twins, the rate is around 9.4%. That gap is surprisingly small compared to many genetic diseases, which tells us that environment and other non-genetic factors play an outsized role.
Many of the implicated genes control how the immune system communicates. Variants in genes that regulate key immune signaling molecules affect how the body calibrates inflammation and tolerance. Other genes influence the physical integrity of the intestinal barrier itself, while still others affect autophagy, the process cells use to clean up damaged components. In rare cases, mutations in a single gene can cause severe colitis in infants within the first weeks of life, but the vast majority of ulcerative colitis involves dozens or hundreds of small genetic contributions acting together.
The Immune System Attacks the Colon
At its core, ulcerative colitis is a disease of immune misdirection. The immune system, which normally tolerates the trillions of harmless bacteria living in the gut, loses that tolerance and launches a sustained inflammatory attack against the colon’s inner lining. This isn’t a brief flare of inflammation that resolves. It becomes chronic and self-reinforcing.
One of the key players is a signaling protein called TNF-alpha. In people with ulcerative colitis, the gut produces excessive amounts of TNF-alpha, which drives inflammation and damages the protective mucosa. This is why some of the most effective treatments for the disease work by blocking TNF-alpha directly.
The intestinal immune system relies on sensors embedded in the gut lining that distinguish between harmless resident bacteria and genuine threats. In a healthy person, these sensors maintain a careful balance, keeping inflammation in check while still defending against pathogens. In someone predisposed to ulcerative colitis, these sensors malfunction. The result is a cascade: the immune system fails to tolerate normal gut bacteria, the balance between inflammation-promoting and inflammation-suppressing immune cells shifts, the intestinal barrier weakens, and healing slows. Each of these effects feeds the others, creating a cycle of chronic tissue damage.
A Weakened Mucus Barrier
The colon is lined with a thick layer of mucus that acts as a physical shield between gut bacteria and the cells underneath. This mucus is built primarily from a protein called MUC2, produced by specialized cells called goblet cells. In people with active ulcerative colitis, MUC2 production drops significantly. The goblet cells become underdeveloped and produce mucus that is structurally immature and poorly formed.
When this barrier thins or breaks down, bacteria that normally stay safely within the gut’s interior can reach the intestinal wall directly. That contact triggers and amplifies the inflammatory response. It’s a bit like removing the protective coating on a wire: the underlying tissue becomes exposed and vulnerable. The reduced mucus isn’t just a consequence of inflammation. It appears to be part of the disease mechanism itself, with inefficient production of MUC2 contributing to the initial breach that lets inflammation take hold.
Gut Bacteria Fall Out of Balance
People with ulcerative colitis have a measurably different community of gut bacteria compared to healthy individuals. Overall bacterial diversity drops by roughly 25%. Certain beneficial groups decline sharply, while potentially harmful species gain ground.
Two of the most notable losses involve bacteria that produce butyrate, a short-chain fatty acid that serves as the primary fuel for colon cells and helps maintain the intestinal barrier. Roseburia hominis and Faecalibacterium prausnitzii, both major butyrate producers, are significantly reduced in people with ulcerative colitis. Another depleted species, Akkermansia muciniphila, plays an important role in maintaining the mucus layer.
On the other side of the ledger, potentially harmful bacteria from groups like Proteobacteria increase. People with ulcerative colitis are also more likely to harbor pathogenic species, including certain strains of E. coli that can adhere to and invade the intestinal lining. Whether the bacterial imbalance triggers the disease or results from the inflammatory environment (or both) remains an active question, but the relationship is clearly bidirectional. Inflammation reshapes which bacteria can thrive, and the altered bacterial community in turn fuels more inflammation.
The Smoking Paradox
One of the most counterintuitive findings in ulcerative colitis research is the relationship with smoking. Current smokers have a lower risk of developing the disease than people who have never smoked. In one large study, men who started smoking between ages 25 and 29 had about an 18% lower risk compared to non-smokers.
But quitting erases that protection and then some. Ex-smokers face a significantly higher risk than people who never smoked at all, and the younger they started smoking, the greater their risk after quitting. Former smokers who began before age 20 had nearly double the risk of developing ulcerative colitis compared to non-smokers. This pattern held strongly in men. In women, the associations were weaker and mostly not statistically significant, except for those who started smoking before 20.
Researchers believe nicotine may alter immune responses in the colon and affect mucus production, but the exact mechanism remains unclear. To be clear, this is not a reason to smoke. The cardiovascular, cancer, and lung disease risks far outweigh any protective effect against ulcerative colitis.
Dietary Fats and the Western Diet
The rapid rise of ulcerative colitis in industrializing countries has drawn attention to diet, particularly the Western pattern of eating. One line of evidence points to linoleic acid, an omega-6 fat found abundantly in soybean oil, corn oil, and many processed foods. Excessive consumption of linoleic acid appears to promote intestinal inflammation through several mechanisms.
In animal studies, a high-fat diet based on soybean oil (which is roughly 55% linoleic acid) increased susceptibility to colitis, while high-fat diets based on olive oil or low-linoleic-acid soybean oil did not. The soybean oil diet disrupted gut bacteria, boosted levels of inflammatory compounds called prostaglandins, and reduced levels of protective molecules in the gut’s own cannabinoid signaling system, which normally helps dampen inflammation. It also promoted the growth of invasive E. coli strains that can use linoleic acid as fuel. Mice genetically predisposed to colitis developed symptoms faster and more severely on the high-linoleic-acid diet, including earlier weight loss and blood in the stool.
These are animal findings, not proof that soybean oil causes ulcerative colitis in humans. But the biological pathways are relevant, and the broader pattern is consistent: populations that shift toward diets high in processed omega-6 fats tend to see rising rates of inflammatory bowel disease.
Early Life and the Hygiene Hypothesis
Ulcerative colitis is far more common in wealthy, urbanized countries, and its incidence rises as developing nations industrialize. The hygiene hypothesis offers one explanation: children raised in very clean environments may not encounter enough diverse microbes early in life to properly train their immune systems. When these individuals encounter certain bacteria later, their immune response may be exaggerated or misdirected.
The evidence is nuanced. Breastfeeding, which exposes infants to beneficial bacteria and immune factors, appears to be protective against ulcerative colitis. One surprising finding from a large Swedish study was that having older siblings actually increased UC risk, possibly because older siblings expose younger children to infections at higher doses or earlier ages than they’d otherwise encounter. General household cleanliness, on the other hand, doesn’t seem to affect risk.
The hygiene hypothesis doesn’t fully explain ulcerative colitis on its own, but it helps account for the geographic and generational patterns. The disease is not simply genetic, because genetics don’t change fast enough to explain the rapid increases seen over the past century. Something about modern living environments, whether it’s sanitation, diet, antibiotic use, or all three, is shifting the immune landscape in ways that make ulcerative colitis more likely.
NSAIDs and Medication Triggers
Common painkillers like ibuprofen and naproxen have long been suspected of triggering ulcerative colitis flares. These drugs are known to damage the gastrointestinal lining, which makes the concern biologically plausible. Some studies have found that people with inflammatory bowel disease who take NSAIDs are about 24% more likely to experience a flare.
However, recent research suggests this association may be misleading. The problem is reverse causality: people often take painkillers because of early symptoms of a flare, like abdominal pain or joint aches, before the flare is formally diagnosed. When researchers accounted for this by examining the rate of flares before and after NSAID use, the apparent risk largely disappeared. The current evidence does not convincingly support a direct causal link between NSAID use and ulcerative colitis flares, though many gastroenterologists still advise caution with these medications in patients who have the disease.
How These Factors Work Together
No single cause explains ulcerative colitis. The most accurate picture is a chain of events that requires multiple links. Genetic variants create a predisposition, particularly in genes governing immune regulation and barrier integrity. Environmental factors, from diet to early microbial exposure, shape the gut’s bacterial community and the immune system’s calibration. At some point, the mucus barrier weakens, bacteria make contact with the intestinal wall, and a genetically primed immune system responds with chronic, self-sustaining inflammation.
This is why the disease runs in some families but skips generations, why identical twins usually don’t share the diagnosis, and why it’s becoming more common in countries adopting Western lifestyles. It’s also why there’s no single treatment that works for everyone. The combination of factors that tips one person into disease is different from the combination in the next.